ZP1848: Phase I data

A double-blind, placebo-controlled, dose-escalation, U.S. Phase I trial in 60 healthy volunteers and 10 Crohn's disease patients in remission showed that doses of up to 96 mg ZP1848 for 2 weeks were w...